Predictive biomarkers of mortality in patients with severe COVID-19 hospitalized in intensive care unit.

Autor:	Dos Santos Medeiros SMFR; Keizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.; Molecular Biology Laboratory (LABIMOL), Medical Sciences Center, Federal University of Paraíba (CCM/UFPB), João Pessoa, Paraíba, Brazil., Sousa Lino BMN; Fundação Oswaldo Cruz (FIOCRUZ), Eusébio, Ceará, Brazil., Perez VP; Molecular Biology Laboratory (LABIMOL), Medical Sciences Center, Federal University of Paraíba (CCM/UFPB), João Pessoa, Paraíba, Brazil.; Department of Physiology and Pathology, Health Sciences Center, Federal University of Paraíba (CCS/UFPB), João Pessoa, Paraíba, Brazil., Sousa ESS; Molecular Biology Laboratory (LABIMOL), Medical Sciences Center, Federal University of Paraíba (CCM/UFPB), João Pessoa, Paraíba, Brazil.; Department of Obstetrics and Gynecology, Medical Sciences Center, Federal University of Paraíba (CCM/UFPB), João Pessoa, Paraíba, Brazil., Campana EH; Molecular Biology Laboratory (LABIMOL), Medical Sciences Center, Federal University of Paraíba (CCM/UFPB), João Pessoa, Paraíba, Brazil.; Department of Pharmaceutical Sciences, Health Sciences Center, Federal University of Paraíba (CCS/UFPB), João Pessoa, Paraíba, Brazil., Miyajima F; Fundação Oswaldo Cruz (FIOCRUZ), Eusébio, Ceará, Brazil., Carvalho-Silva WHV; Department of Immunology, Instituto Aggeu Magalhães (IAM/FIOCRUZ-PE), Recife, Pernambuco, Brazil., Dejani NN; Molecular Biology Laboratory (LABIMOL), Medical Sciences Center, Federal University of Paraíba (CCM/UFPB), João Pessoa, Paraíba, Brazil.; Department of Physiology and Pathology, Health Sciences Center, Federal University of Paraíba (CCS/UFPB), João Pessoa, Paraíba, Brazil., de Sousa Fernandes MS; Keizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil., Yagin FH; Department of Biostatistics and Medical Informatics, Faculty of Medicine, Inonu University, Malatya, Türkiye., Al-Hashem F; Department of Physiology, College of Medicine, King Khalid University, Abha, Saudi Arabia., Elkholi SM; Department of Rehabilitation Sciences, College of Health and Rehabilitation Sciences, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia., Alyami H; Department of Medical and Surgical Nursing, College of Nursing, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia., Souto FO; Keizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Aug 30; Vol. 15, pp. 1416715. Date of Electronic Publication: 2024 Aug 30 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1416715
Abstrakt:	Objectives: This study was performed to identify predictive markers of worse outcomes in patients with severe COVID-19 in an intensive care unit. Methods: Sixty patients with severe COVID-19, hospitalized in the Intensive Care Unit (ICU) between March and July 2021, were stratified into two groups according to the outcome survivors and non-survivors. After admission to the ICU, blood samples were collected directly for biomarker analysis. Routine hematological and biochemical biomarkers, as well as serum levels of cytokines, chemokines, and immunoglobulins, were investigated. Results: Lymphopenia, neutrophilia, and thrombocytopenia were more pronounced in non-surviving patients, while the levels of CRP, AST, creatinine, ferritin, AST, troponin I, urea, magnesium, and potassium were higher in the non-surviving group than the survival group. In addition, serum levels of IL-10, CCL2, CXCL9, and CXCL10 were significantly increased in patients who did not survive. These changes in the biomarkers evaluated were associated with increased mortality in patients with severe COVID-19. Conclusion: The present study confirmed and expanded the validity of laboratory biomarkers as indicators of mortality in severe COVID-19. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 dos Santos Medeiros, Sousa Lino, Perez, Sousa, Campana, Miyajima, Carvalho-Silva, Dejani, de Sousa Fernandes, Yagin, Al-Hashem, Elkholi, Alyami and Souto.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu